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ABSTRACT
Although drugable fibroblast growth factor receptor (FGFR) alterations in squamous 
cell carcinomas (SCC) of various entities are well known, little is known about FGFR 
modifications in squamous differentiated bladder cancer. Therefore, our study evaluated 
FGFR1-3 alterations as a putative therapeutic target in this subgroup. We analyzed 
73 squamous differentiated bladder cancers (n = 10 pT2, n = 55 pT3, n = 8 pT4) for 
FGFR1-3 protein expression, FGFR1-3 copy number variations, FGFR3 chromosomal 
rearrangements (fluorescence in situ hybridization (FISH)) and FGFR3 mutations 
(SNapShot analysis). Only single cases displayed enhanced protein expression, most 
frequently FGFR3 overexpression (9.4% (6/64)). FISH showed no amplifications of 
FGFR1, 2 or 3. Break apart events were only slightly above the cut off in 12.1% (8/66) of 
cases and no FGFR3-TACC3 rearrangements could be proven by qPCR. FGFR3 mutations 
(p.S249C) were found in 8.5% (6/71) of tumors and were significantly associated 
with FGFR3 protein overexpression (p < 0.001), and unfavourable clinical outcome 
(p = 0.001). Our findings are consistent with the results of the TCGA data set for the 
“squamous-like” subtype of bladder cancer (n = 85), which revealed reduced overall 
expression of FGFR1 and FGFR2 in tumors compared to normal tissue, while expression 
of FGFR3 remained high. In the TCGA “squamous-like” subtype FGFR3 mutations were 
found in 4.9% and correlated with high FGFR3 RNA expression. Mutations of FGFR1 and 
FGFR2 were less frequent (2.4% and 1.2%). Hence, our comprehensive study provides 
novel insights into a subgroup of squamous differentiated bladder tumors that hold clues 
for novel therapeutic regimens and may benefit from FGFR3-targeted therapies.
INTRODUCTION
Bladder cancer is histopathologically a 
heterogeneous group comprising urothelial carcinoma 
(UC), squamous cell carcinoma (SCC), adenocarcinoma 
and neuroendocrine tumors (small cell carcinoma). 
About 90% of bladder cancers in western countries 
are histologically classified as UC, and SCC comprise 
< 3% of the tumors [1]. However, recent cluster analysis 
of whole genome expression data has identified breast 
cancer-like “basal” and “luminal” types of muscle invasive 
UC with a distinct “squamous-like” subtype [2–4]. This 
subtype shows high level expression of high molecular 
weight keratins (KRT5, KRT6, KRT14), EGFR and 
an invasive/metastatic phenotype with shorter survival 
times similar to SCC of the bladder. So far, cystectomy 
is the main treatment strategy for muscle invasive 
UC, SCC or mixed UC with squamous differentiation. 
The value of neoadjuvant chemotherapy remains 
controversial, as on the one hand there is evidence for 
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superiority in cases with mixed histopathology and on 
the other hand the consequent delay of cystectomy in 
squamous differentiated tumors is associated with poor 
response rates  [5]. 
At the molecular level, UC and squamous 
carcinomas of other sites (e.g. lung and head and neck) 
share pathways such as fibroblast growth factor receptor 
(FGFR)-signaling [6]. This tyrosine kinase receptor 
family comprises four different FGFRs (FGFR1-4), 
which control cell survival and differentiation mainly 
via the Ras/MAPK, STAT and PI3K pathway [7]. In UC, 
pathway activation results primarily from point mutated 
FGFR3, which is particularly frequent in low grade 
non-invasive bladder cancers [8]. FGFR3 mutation and 
protein overexpression in invasive UC is less frequent 
(12.6%) [3]. Previous work from our group showed 
that amplification of FGFR genes is rare in UC (1.6% 
FGFR1, 0.8% FGFR2, 3.4% FGFR3) [9], and also that 
the recently discovered FGFR3 gene fusions (resulting in 
FGFR3-TACC3 or FGFR3-BAlAP2L1) were only found 
in a small subgroup of UCs (2/32, 6.25%) [10]. Other 
FGFR-driven cancers with squamous differentiation 
include squamous carcinomas of the lung and head 
and neck [6]. In squamous lung cancer, amplification 
of FGFR1 was found in up to 22% of cases [11].  This 
was associated with reduced cell growth in vitro in cells 
treated with a small molecule inhibitor [12]. However, 
little is known about FGFR activation in squamous 
differentiated bladder cancer. Hence, we systematically 
screened a cohort of squamous differentiated specimens 
and publically available datasets of “squamous-like” 
bladder cancers for expression, amplification, mutation 
and chromosomal rearrangement of FGFRs (FGFR1-3), 
in order to evaluate putative pathway activation. Our aim 
was to evaluate FGFRs as potential therapeutic targets in 
squamous differentiated bladder cancer, a tumor group in 
which disease management remains inadequate. 
RESULTS
FGFR1, FGFR2 and FGFR3 gene amplification 
in squamous differentiated bladder cancer
Fluorescence in situ hybridization (FISH) was 
successfully evaluated in a total of 68 samples for FGFR1, 
65 samples for FGFR2 and 64 samples for FGFR3. Among 
all suitable samples, no amplification of FGFR1, FGFR2 or 
FGFR3 matching the criteria defined by Schildhaus et al. 
[13] were found (Supplementary Data S1). 
Similar to a previous study from our group we then 
analyzed the cells for polysomy, choosing a cut-off of 
three centromere signals for polysomy [9]. We identified 
only 4/68 (5.9%), 3/65 (4.6%) and 0/64 polysomic cases 
for chromosome 8 (FGFR1), 10 (FGFR2) and 4 (FGFR3), 
respectively, indicating no considerable amplification bias 
due to polysomy (Supplementary Data S1).
FGFR3-rearrangement analysis (break apart 
FISH and cDNA fragment analysis)
FISH analysis for FGFR3 rearrangement was 
effectively performed on a total of 66 samples. For 
each tissue microarray we evaluated cores of normal 
urothelium, showing a mean of 4.22 break apart events. 
According to Wolff et al. we calculated a cut off for 
positive cases by using the Microsoft Excel β-inverse 
function BETAINV [14]. Tumor samples were scored as 
positive, if nine or more break apart events in 60 tumor 
cell nuclei were found (Figure 1, Supplementary 
Data S1). We identified only eight slightly positive 
samples (ranging from 9 to 11 break apart events, 
mean 9.5 events/sample). There was no overlap with 
the polysomic samples mentioned above. Additional 
cDNA fragment analysis of FISH-positive cases showed 
sufficient FGFR3-cDNA in two available frozen samples 
(ID #2, #18), but no FGFR3-TACC3-fusion product 
could be verified.
FGFR3 mutation analysis and its  
clinical impact 
We investigated the squamous differentiated 
bladder cancers for activating FGFR3 point mutations. 
SNapShot®-analysis showed FGFR3 mutations in 6 of 
71 samples (8.5%, all p.S249C, n = 3 pure squamous 
carcinomas and n = 3 mixed carcinomas) (Figure 2A, 
Supplementary Data S1). Next, we determined whether 
there were associations between FGFR3 mutation and 
clinico-pathological characteristics. A close association 
of FGFR3 mutation and FGFR3 protein overexpression 
(p < 0.001; Fisher’s exact test) was demonstrated. 
No correlations were found with stage, grade, age at 
diagnosis or gender (Table 1). Even though FGFR3 
mutation was rare in this cohort, we analyzed the 
recurrence-free survival as a clinical indicator that is 
known being associated with FGFR3 mutation in bladder 
cancer [8]. Kaplan-Meier analysis revealed that patients 
with a p.S249C FGFR3 mutation showed a significantly 
(p = 0.001) shorter recurrence-free survival (mean RFS: 
7.5 months ± 1.8; 95% CI: 3.9 to 11.1) compared with 
those with non-mutated tumors (mean RFS: 105.8 months 
± 10.2; 95% CI: 85.8 to 125.7) (Figure 2B, Table 2). The 
calculated Cox regression model (including the potentially 
prognostic parameters grade, tumor stage, nodal status 
and metastasis) confirmed the clinical impact of FGFR3 
mutation on recurrence-free survival (Supplementary 
Data S2). Squamous differentiated bladder cancer 
patients displaying a p.S249C mutation had a 
4.4-fold increased risk for tumor relapse (multivariate 
hazard ratio (HR): 4.4, 95% CI: 1.0 to 21.8, p = 0.046). 
However, mutation status had no significant influence on 
disease-specific survival or overall survival in our patient 
cohort (data not shown).
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FGFR1-3 protein expression in bladder cancer
Protein expression was analyzed by 
immunohistochemical staining and 60, 58 and 64 
TMA cores for FGFR1, FGFR2 and FGFR3 could be 
scored. Evaluation criteria used to define FGFR protein 
expression were 0 (no expression), 1 (weak expression), 
2 (intermediate expression) and 3 (strong expression) 
as reported by Tomlinson et al. [15]. FGFR1 expression 
was very low, with 52/60 (86.7%) tumors exhibiting 
no expression, 6/60 (10%) with weak expression and 
2/60 (3.3%) tumors showing strong expression. FGFR2 
expression was similarly low: 49/58 (84.5%) displayed 
no, 7/58 (12.1%) weak and 2/58 (3.4%) strong positivity. 
FGFR3 protein expression was negative in 14/64 (21.9%) 
cases, weak in 34/64 (53.1%), intermediate in 10/64 
(15.6%) and strong in 6/64 (9.4%) of the examined 
cores  (Figure 3). There was no statistical correlation 
of FGFR1-3 expression with any clinico-pathological 
parameter (see Supplementary Data S3).
External validation of FGFR alterations in an 
independent cohort of bladder cancer (TCGA)
After integration of all currently available bladder 
cancer datasets new hierarchical cluster analysis based on 
the mRNA expression of the entire TCGA cohort identified 
85 “squamous-like” bladder cancer samples (Figure 4). 
The new cluster of “squamous-like” tumor samples was 
consistent with the results previously published [16]. 
Mutation and CNV data was available for n = 82 samples. 
Mutations of FGFR1, FGFR2 and FGFR3 were present 
in 2/82 (2.4%), 1/82 (1.2%), and 4/82 (4.9%) of tumors.
The average expression of FGFR1 and FGFR2 was 
significantly lower (p < 10−6) in “squamous-like” tumors 
compared to normal tissues (95% CI; factor 4.8–10 
(FGFR1) and 2.5–5.1 (FGFR2)) (Figure 5). Furthermore, 
there was a significant positive correlation between the 
expression of FGFR1-FGFR2 (ρ = 0.24, p = 0.026) and 
FGFR2-FGFR3 (ρ = 0.23, p = 0.031) in tumor tissues, 
while FGFR1 expression was inversely correlated with 
Figure 1: FISH images of ZytoLight SPECTM FGFR3 Dual Color Break Apart Probe sample ID 51. (A) Tumor cell nucleus 
(*) with a classical break apart event of chromosome region 4p16.3 displaying one single orange (proximal to FGFR3) and one single 
green (distal to FGFR3) signal as well as one fusion (adjacent orange-green) signal. (B) Tumor cell with normal chromosome region 4p16.3 
showing two fusion signals (adjacent orange-green signals) per nucleus. DAPI counterstain, original magnification 1000-fold, white scale 
bar equals 2 µm.
Figure 2: FGFR3 mutation analysis of our squamous differentiated bladder cancer samples (n = 71). (A) Frequency of 
FGFR3 mutations (8.5%) in our squamous bladder tumors. (B) Univariate Kaplan-Meier survival curve illustrating recurrence-free survival 
(RFS) of patients with FGFR3 mutation (dashed gray line) compared to non-mutated tumors (black line). Vertical lines: censored cases.
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FGFR3 expression (ρ = −0.30, p = 0.005). Compared to 
normal tissues, the average expression of FGFR3 was 
significantly higher in tumors with concomitant FGFR3 
mutation (p = 0.006), but not in those without (Figure 5). 
Due to the small number of FGFR3 mutated tumors a 
reliable estimate of the effect size was not possible (95% 
CI; factor 2-34).
The calculated copy numbers of FGFR1, FGFR2 
and FGFR3 deviated from the normal genotype of 
blood and normal tissue samples in the majority of the 
“squamous-like” tumors, indicating the general genomic 
instability of progressed cancers. High level amplifications 
of FGFR1, FGFR2 and FGFR3 segments (average of 
gene copies per chromosome > 2) were detected in 3/82 
(3.7%), 0/82 (0%) and 0/82 (0%) of the tumors (Figure 4). 
Futhermore, 5/82 (6.1%) patients had a less distinctive 
elevated copy-number of FGFR1 (average gene copies 
per chromosome > 1.5). There was no evidence for deep 
deletion (average gene copies per chromosome < 0.5) of 
the FGFR1, FGFR2 and FGFR3 genes. 
DISCUSSION
Aberrant activation of tyrosine kinase signaling is 
frequent in various tumors and offers several possibilities 
for targeted therapies.  We focused on FGFRs, since FGFR 
alterations have been found in SCC tumors in other tissues 
and FGFR3 is frequently activated in UC [6, 8]. Our study 
is the first comprehensive analysis of FGFR alterations 
potentially contributing to the development of squamous 
differentiated bladder cancer. We initially studied gene 
copy number alterations, i.e. FGFR amplifications, as a 
known mechanism of enhanced FGFR gene activation. 
While FGFR1 amplifications have been found in up 
to 22% of squamous cell carcinomas of the lung and 
about 15% in head and neck cancers, we found neither 
FGFR1, FGFR2, nor FGFR3 amplifications by FISH 
in squamous differentiated bladder cancer [11, 17]. In a 
previous study of UC by our group we detected only low 
numbers of amplifications varying from 1.6%, 0.8% and 
3.4% respectively for FGFR1, FGFR2 and FGFR3 [9]. 
Table 1: Clinico-pathological and demographic data of our squamous differentiated bladder cancer 
samples cohort in relation to FGFR3 mutation status
variable patients (na) non-mutated (n) mutated (n) p-valueb
patient age (years)     
0–67.5 36 34 2
0.377
 > 67.5 35 31 4
gender     
female 39 35 4
0.549
 male 32 30 2
tumor stage     
pT1-2 9 9 0
0.333
 pT3-4 62 56 6
grade     
 G1-2 21 20 1
0.472
 G3-4 50 45 5
nodal status     
N0 52 48 4
0.877
 N1 11 10 1
FGFR3 expression     
low expression (Tomlinson-Score < 3) 55 52 3
< 0.001high expression
(Tomlinson-Score = 3) 6 3 3
Bold-face indicates significant results.
a Variations in number due to limited histopathological, experimental or clinical follow up data.
bCalculated by Fisher’s exact test.
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Thus, our data do not indicate FGFR amplification as a major 
mechanism of pathway activation in these bladder cancer 
subtypes. Contrary to our negative FGFR1-FISH results, 
Helsten et al. found up to 7% of FGFR1 amplification 
in their high throughput next-generation sequencing 
pan-cancer study [6]. However, 3% of FGFR3 amplifications 
are comparable with our previous findings in UC. 
Besides FGFR amplification, recent studies have 
identified FGFR gene fusion products such as FGFR3-
TACC3 as an additional oncogenic mechanism and a 
putative target for tyrosine kinase inhibitors in a variety 
of tumors e.g. adeno- and squamous cell carcinoma 
of the lung, glioblastoma multiforme and bladder 
cancer [10, 18, 19]. Full-length FGFR3-TACC3 gene 
fusion products led to anchorage independent growth 
and constitutive activation, resulting in increased 
phosphorylation compared to FGFR3 wild type receptors 
[10]. In addition, the fusion products are reported 
to stimulate proliferation by inducing chromosomal 
instability and aneuploidy [19]. FGFR3-TACC3 fusions 
were found in 2.3% (3/131) samples of the TCGA bladder 
cancer cohort [3] and overall FGFR fusions were reported 
by Helsten et al. in 6% of their bladder cancer specimens 
(FGFR3-TACC3 fusions 3%) [6]. We found eight tumors 
with only slightly enhanced break apart events by FISH 
analysis. However, further successful analysis was limited 
to cryo samples only (n = 2), and fusion products could not 
be confirmed by PCR. Therefore, it remains unresolved 
whether visible break apart events might be caused by 
section artifacts or might be unverified due to limited 
PCR performance using fragmented paraffin-derived RNA 
or the presence of other fusion partners. Nevertheless, 
FGFR3-TACC3 fusions seem to be infrequent alterations 
in squamous differentiated bladder cancers. 
The most common mechanism leading to FGFR3 
activation in bladder cancer is activating point mutation 
of the gene. By creating two unpaired cysteine residues, 
the common point mutations induce a ligand-independent 
Table 2: Clinico-pathological data of our squamous differentiated bladder cancer samples in 
regard to recurrence-free survival
variable patients (na)
recurrence (n)
yes                                  no p-value
b
metastasis status     
no metastasis 49 13 36
< 0.001
 metastasis 7 7 0
tumor stage    
pT1-2 8 0 8
0.038
 pT3-4 55 20 35
grade    
 G1-2 20 5 15
0.185
 G3-4 43 15 28
nodal status    
N0 51 17 34
0.176
 N1 6 2 4
mutational status    
wildtype 57 16 41
0.001
 p.S249C 5 4 1
FGFR3 expression     
low expression
(Tomlinson-Score < 3) 50 14 36
0.144
 high expression(Tomlinson-Score = 3) 5 3 2
Bold-face indicates significant results.
aVariations in number due to limited histopathological, experimental or clinical follow up data.
bCalculated by log-rank test.
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receptor activation by forming disulfide-linked receptor 
dimers, leading to activation of the Ras/MAPK, STAT 
or PI3K pathway [7]. FGFR3 mutations are reported 
in up to 50% of cancers of all stages from the lower and 
upper urinary tract with p.S249C being the most common 
mutation, found in 61% of cases [7]. Mutation is inversely 
correlated with tumor stage and grade [15], and mutated 
tumors are associated with a favorable clinical outcome 
[8, 15, 20]. Despite the high mutation frequencies in 
urothelial carcinoma, the role of FGFR3 mutations in 
squamous differentiated bladder cancers is not well 
defined. In our study 6 of 71 (8.5%) tumor samples (n = 3 
pure squamous carcinomas and n = 3 mixed carcinomas) 
contained an FGFR3 p.S249C mutation, all of them being 
grade 2 or higher and stage 3 or higher. This is slightly less 
than the frequency in invasive urothelial carcinomas reported 
by the TCGA project (12%) [3] and the n = 126 UC samples 
of Helsten et al. (15%) [6]. Thus, we suggest that FGFR3 
mutation (and FGFR3 mRNA expression) plays a minor role 
in squamous tumorigenesis. However, our survival analysis 
revealed an association between FGFR3 mutation and an 
increased risk of recurrence in squamous differentiated 
bladder cancers which has also been shown previously for 
low grade non-invasive UC [8]. Analysis of all invasive 
bladder cancer TCGA samples displayed a worse prognosis 
for tumors with p.S249C mutation, whereas other FGFR3 
mutations were associated with good prognosis (data not 
shown). Thus, mutation analysis potentially allows a further 
stratification of patients, and should be further evaluated in 
larger cohorts of invasive tumors. 
Interestingly, there was no difference between pure 
squamous cell carcinoma and mixed carcinomas with 
squamous differentiation, and validation by a subgroup 
analysis of the “squamous-like” TCGA subgroup 
showing 4.9% of FGFR3 mutations corroborated our 
results. In addition, mRNA expression analysis of the 
“squamous-like” TCGA subgroup confirmed generally 
low levels of FGFR1-3 mRNA in tumors, except in 
FGFR3 mutated ones. Consistent with these findings, five 
of the six tumors (83.3%) harboring FGFR3 mutations 
also showed enhanced FGFR3 protein expression, i.e. 
Tomlinson Score 2 or 3. This observation is consistent 
Figure 3: FGFR1-3 protein expression of our squamous differentiated bladder cancer samples. Distribution of protein 
expression measured by Tomlinson Score 0-3 for FGFR1 (A) n = 60, FGFR2 (B) n = 58, FGFR3 (C) n = 64, respectively. (D–F) anti-
FGFR3 staining with examples of Tomlinson Score 1(D), 2(E) and 3(F), original magnification 200-fold. Black scale bar equals 100 µm. 
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Figure 4: Heatmap showing the FGFR1, FGFR2 and FGFR3 mRNA expression in the 85 “squamous-like” bladder 
cancer samples identified by hierarchical cluster analysis of the entire TCGA cohort. Samples are annotated with gender, 
stage, grade, histological subtype as well as mutational status and CNVs for FGFR1-3.
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with the reported correlation of FGFR3 overexpression 
and mutation in urothelial bladder cancer [15, 21]. 
Overall, protein expression of FGFR1, 2 and 3 was weak 
and we could not verify an overexpression of FGFR2 in 
squamous bladder cancers (18%) as reported by Youssef 
et al. in their squamous bladder cancer cohort from Egypt 
[22]. However, irrespective of the presence of FGFR3 
mutation, increased FGFR3 protein expression was found 
in 16/64 (25%) of our squamous differentiated cancers, 
mostly in G3 tumors (75%). The mechanism of protein 
overexpression in wild-type tumors is still not fully 
understood [15]. Statistical analysis of our cohort showed 
no significant association of FGFR3 overexpression (i.e. 
Tomlinson Score 3) with recurrence free (RFS), disease 
specific (DSS) or overall survival (OS) (data not shown). 
This is in line with previous results of our group for 
FGFR3 in urothelial carcinomas [9]. However, Sung 
et al. reported a worse prognosis (OS, DSS) of FGFR3 
overexpressing muscle-invasive bladder cancers treated 
with adjuvant chemotherapy [23]. Due to lack of treatment 
information for our cohort we could not further analyze 
refined subgroups, but probably such a subgroup would 
benefit from targeted anti-FGFR3 therapy.   
In light of our novel findings, we suggest a minor 
role for FGFR alterations in the small subgroup of 
non-bilharzial squamous bladder cancers.  However, 
bearing in mind that recurrence-free survival is an 
indicator for disease severity and risk of progression, 
FGFR3 mutations in squamous differentiated bladder 
tumors may indicate potential for FGFR inhibitor 
treatment in these tumors. This will be particularly 
interesting as some FGFR inhibitors have been approved 
by the FDA for the treatment of solid cancers. Currently 
five clinical trials (www.clinicaltrials.gov [24]; identifier 
NCT02401542, NCT02529553, NCT02278978, 
NCT01732107, NCT01004224) are assessing the effects 
of FGFR inhibitors in bladder and other cancers.  
MATERIALS AND METHODS
Patient samples, data and ethics
Tissue microarrays (TMA) of previously 
characterized formalin-fixed, paraffin-embedded 
squamous differentiated bladder cancer specimens were 
used [25]. The residual TMAs contained 34 cases of pure 
squamous cell carcinomas (5 pT2, 24 pT3, 5 pT4) and 39 
cases with mixed squamous and urothelial differentiation 
(5 pT2, 31 pT3, 3 pT4). Mixed tumors used for subsequent 
analyses contained at least 33.3% of squamous cells. 
Varying numbers of evaluated cases were due to limited 
experimental or clinical follow up data. 
The local Ethics Committee approved the 
anonymous use of samples and clinico-pathological data 
(EK 173/06, 9/12). Clinico-pathological and follow-up 
data of patients are shown in Supplementary Data S4. 
Fluorescence in situ hybridization analysis 
(FISH)
Hybridization of ZytoLight Dual Color Probes 
SPEC FGFR1/CEN 8, SPEC FGFR2/CEN 10, SPEC 
FGFR3/CEN 4 and ZytoLight SPEC FGFR3 Dual Color 
Break Apart Probe (Zytovision, Bremerhaven, Germany) 
onto 3 µm TMA sections was performed according to 
the manufacturer’s protocols. Slides were reviewed on a 
Zeiss Axiovert 135 fluorescence microscope (Carl Zeiss, 
Oberkochen, Germany), and Diskus Software (Büro 
Hilgers, Königswinter, Germany) was used to capture 
images from different channels/filters (AHF ZyGreen 
Figure 5: mRNA expression of FGFR1, 2 and 3 in the “squamous-like” bladder cancer subtype of the TCGA cohort. 
Pairwise applied Welch’s t-tests indicate that the average expression of FGFR1 and FGFR2 was significantly lower (p < 10−6) in non-
mutated tumors (T) compared to normal tissue (N), while FGFR3 mRNA expression in mutated tumors (T(mut.)) was significantly higher 
(p = 0.02). ** = p < 0.01, *** = p < 0.001.
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F36-720, AHF ZyOrange F36-740, AHF DAPI, AHF 
F56-700). The numbers of FGFR signals and centromere 
signals were counted in 60 nuclei of tumor cells at high 
magnification (x1000), and the FGFR/centromere ratio 
was classified into high- and low-level amplifications or 
a normal ratio as previously defined [13]. Likewise, 60 
tumor cell nuclei were analyzed for break apart events 
(split signals with minimal distance of two signals or 
single signals). Specimens were classified “positive for 
FGFR3 rearrangements” according to a calculated cut 
off value, determined on 60 nuclei of normal urothelium, 
using the Microsoft Excel BETAINV function reported by 
Wolff et al. [14].
DNA isolation and FGFR3 mutation analysis
As described previously, tumor DNA was extracted 
from microdissected serial sections of the residual tissue 
blocks using QIAamp™ DNA Mini Kit (Qiagen, Hilden, 
Germany) [9]. Analysis of 11 known activating FGFR3 
point mutations was performed by SNaPshot® Multiplex 
System assay (Applied Biosystems, Foster City, USA) as 
described previously [26, 27]. 
RNA-isolation, cDNA-synthesis and PCR-fragment 
analysis for FGFR3 gene fusions
RNA was extracted from either microdissected 
FFPE samples using the RNEasy FFPE Kit (Qiagen, 
Hilden, Germany) or microdissected from frozen tissue 
using the Arcturus® PicoPure® RNA Isolation Kit (Applied 
Biosystems/Life Technologies, Foster City, USA) 
according to the manufacturer’s instructions. cDNA was 
synthesized with Promega Kit A3500 (Promega, Madison, 
WI, USA). 
FGFR3-TACC3 fusions were assessed by PCR, 
adapted from Williams et al. [10], using an FGFR3 
forward primer (positioned in FGFR3 exon 18) and four 
different reverse primers localized in exons 4, 9, 11 and 
13 of TACC3 covering the most common FGFR3-TACC3 
fusions (for primer sequences and expected PCR product 
sizes see Supplementary Data S5A and S5B). RT4 cell line 
cDNA was used as a positive control for the fusion PCRs 
and cDNA quality was tested with a control PCR (both 
primers localized on FGFR3: FGFR3 14F and FGFR3 
16R) resulting in a 400 bp product. 
Immunohistochemical analysis of FGFR1-3 
protein expression
Immunohistochemical staining for FGFR1, FGFR2 
and FGFR3 was performed on 3 µm TMA sections 
after heat-induced antigen retrieval (EnVision™ FLEX 
Target Retrieval Solution, Low pH, K8005, DAKO 
PT-Link, DAKO, Hamburg, Germany) according to 
the manufacturer’s protocols. The primary antibodies 
(anti-FGFR3, mouse monoclonal clone B9, dilution 1:25 
(Santa Cruz Biotechnology, Heidelberg, Germany), anti-
FGFR2, mouse monoclonal clone 1G3, dilution 1:400 
(www.antikoerper-online.de, Aachen, Germany) and anti-
FGFR1, rabbit polyclonal, dilution 1:100 (Sigma, St. Louis, 
MO, USA)) were linked with DAKO EnVision™FLEX 
system and visualized with DAKO Liquid DAB Substrate 
Chromogen System in a DAKO Autostainer plus (K8024, 
K3468, DAKO). FGFR1, FGFR2 and FGFR3 positivity 
was assessed according to a semi-quantitative scoring 
system reported by Tomlinson et al. [15].
Validation of FGFR alterations in an 
independent set of “squamous-like”  
bladder cancers
For external validation datasets of a “squamous-
like” subtype of chemotherapy-naive, high-grade muscle-
invasive urothelial bladder carcinomas from The Cancer 
Genome Atlas (TCGA) were used [3]. Subtyping was 
performed based on mRNA expression information 
(Illumina Genome Analyzer and Illumina HiSeq 
2000 RNASeqV2 Platforms; Level 3) of all currently 
accessible tumor samples (https://tcga-data.nci.nih.gov/
tcga/findArchives.htm) [28] as previously published 
(for details see Supplementary Data S6) [16]. This approach 
identified 85 bladder cancer samples with a “squamous-
like” gene expression profile from all 408 bladder cancer 
samples. For clinico-pathological parameters of the TCGA 
cohort see Supplementary Data S7.
Data on gene copy number variations (CNV; 
Affymetrix Genome-Wide SNP Array 6.0 with a fixed 
probe set and Illumina HiSeq Platforms; Level 3), somatic 
mutations (Illumina Genome Analyzer and Illumina 
HiSeq2000 DNASeq Platform; Level 3), and mRNA 
expression were analyzed. For samples with CNV data 
from both platforms or multiple segments within the 
gene region, values were summarized by extracting the 
maximum absolute value. Deviating from this one tile 
that was based on two probes, likely caused by a SNP, 
was removed for CNV analysis of FGFR1 in one sample 
(TCGA-ZF-AA4N-01). Data on somatic mutations were 
joined and a gene was assessed as mutated, if at least one 
non-silent mutation was reported within the gene body. 
Quantile normalized mRNA expression values were log2-
transformed to reduce skewness prior to any statistical tests.
Statistical analysis
Statistical analyzes of our experimental data were 
accomplished with SPSS software version 22.0 (SPSS 
Inc., Chicago, USA). Two-sided p-values less than 
0.05 were considered significant. Statistical associations 
between clinico-pathological and molecular factors were 
determined by Fisher’s exact test. Survival curves for 
recurrence-free survival (RFS), disease-specific survival 
Oncotarget10www.impactjournals.com/oncotarget
(DSS) and overall survival (OS) were calculated using 
the Kaplan-Meier method with log-rank statistics. RFS/
DSS/OS were measured from surgery until local or distant 
relapse/tumor death/death and were censored for patients 
alive without evidence of relapse/tumor related death/
death at the last follow-up. Multivariate Cox-regression 
analysis was performed to test for an independent 
prognostic value of FGFR3 mutations.
The evaluation of TCGA data was performed in R 
[29]. For cluster analysis routines from additional software 
packages were used (Supplemental Digital Content 4) 
[30–34]. Pairwise comparison of mRNA expression 
between groups was tested by Welch’s t-test. Correlations 
between the expression of genes were determined by 
Spearman rank correlation coefficient.
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